Your choices go into the PDF (cover and captions); this bar does not.
Rebalix
Comparison report · official data side by side

PSP5 vs AQUIL


PSP5Amundi PEA S&P 500 UCITS ETF Acc
FR0011871128 · Equity · United States · Large cap
AQUILFineco AM Amundi S&P 500 UCITS ETF Acc
IE0002DC0IL1 · Equity · United States · Large cap
Open the interactive comparison on rebalix.com →

Comparison window: · currency: 🇪🇺 EUR · inflation: 🇮🇹 Italy · distributions: reinvested where declared

Report produced on 5 September 2026 · data as of the dates shown per section
Sources: official issuer documents (KID, factsheet, declared NAV series and holdings), ESMA register, ECB rates, Eurostat
Public methodology: rebalix.com/en/methodology

Informational document generated by rebalix.com — facts side by side, no recommendations. It does not constitute investment advice or investment research under Directive 2014/65/EU (MiFID II). Past performance is not indicative of future results.

RebalixPSP5 vs AQUIL · report of 5 September 2026

The funds at a glance

From official issuer documents and the ESMA register
PSP5FR0011871128Amundi PEA S&P 500 UCITS ETF AccEquity · United States · Large cap
Declared index
S&P 500 Net Total Return Index
TER
0.12%
Transaction (KID)
0.00%
Fund size
1.2 mld EUR
Launch
20 May 2014
Currency
EUR
Replication
Synthetic (swap)
Hedging
No
Holdings
79
Effective 🇮🇹 rate
AQUILIE0002DC0IL1Fineco AM Amundi S&P 500 UCITS ETF AccEquity · United States · Large cap
Declared index
S&P 500 Net Total Return Index
TER
0.10%
Transaction (KID)
0.00%
Fund size
1 mln EUR
Launch
21 Jul 2026
Currency
EUR
Replication
Physical
Hedging
No
Holdings
1
Effective 🇮🇹 rate
26.00%

Tracking difference — year by year

Fund minus index, from issuer-declared series (complete calendar years). Each measures adherence to its OWN index.
PSP53y avg: +0.07%/anno
2025
−0.09%
2024
+0.03%
2023
+0.27%
2022
+0.17%
2021
+0.34%
2020
+0.52%
AQUILn/d
not honestly computable
Rebalix · PSP5 vs AQUILsection 1 of 2
RebalixPSP5 vs AQUIL · report of 5 September 2026

Full comparison table

"—" = not published by the source, never estimated
PSP5Amundi PEA S&P 500 UCITS ETF Acc · FR0011871128 · Equity · United States · Large cap
AQUILFineco AM Amundi S&P 500 UCITS ETF Acc · IE0002DC0IL1 · Equity · United States · Large cap
MetricPSP5AQUILNote
Identity
CategoryEquity · United States · Large capEquity · United States · Large capRebalix engine classification
ReplicationSynthetic (swap)Physicalas declared by the issuer
Currency hedgingNoNosource: class name, factsheet
Income policyaccumulatingaccumulating
Costs
TER0.12%0.10%from the KID
Transaction costs (KID)0.00%0.00%internal
All-in cost0.12%0.10%TER + transaction
Tracking difference (3a)+0.07%vs its OWN index
Performance in euro (ECB rates)
1 year+22.1%
3 years+64.0%
5 years+84.0%
10 years+293.5%— = series younger than the window
Risk · last 3 years
Volatility (ann.)+15.80%
Max drawdown−22.42%
Sharpe0.93risk-free = ECB MRO avg
Sortino1.32like Sharpe, downside only
Italian taxation
Effective capital-gains rate26.00%white list, current half-year
Documents & exchanges
Listing venues61ESMA register
Borsa Italiana tickerAQUIL
Indicative cumulative cost: on 10,000 euro over 5 years (stated assumption: 5%/yr growth, cost = TER + transaction) ~76 euro PSP5 · ~66 euro AQUIL. Broker costs not included.

Disclaimer

This document is for information only and does not constitute investment advice under Directive 2014/65/EU (MiFID II), investment research, a personal recommendation, or an offer or solicitation to buy or sell financial instruments.

Past performance is not indicative of, nor a guarantee of, future results. The value of an investment can go down as well as up and investors may not get back the capital invested. Euro returns are affected by currency fluctuations.

Before any investment decision, read the KID and the Prospectus, available from the issuers. Tax treatment depends on individual circumstances and may change.

Data come from official issuer documents and public registers, following the public methodology at rebalix.com/en/methodology. "—" fields were not published by the source and have not been estimated. Rebalix receives no compensation from the issuers mentioned.

Rebalix · PSP5 vs AQUILsection 2 of 2